For this study, peripheral blood samples were collected from human volunteers. Mononuclear cells (MNC) were separated by density centrifugation and were induced to differentiate into endothelial progenitor cells (EPCs) in vitro. Different concentrations of rapamycin and silymarin were introduced to the EPCs over 24 hours and then EPCs were analyzed for proliferation, migration, apoptosis and angiogenesis. Compared with the control group, rapamycin (1, 10, 100 ng/mL) inhibited the proliferation and migration of EPCs in a concentration dependent manner (P<0.05). Silymarin (50, 100 μg/mL) enhanced the proliferation and migration of EPCs and inhibited apoptosis in a concentration dependent manner (P<0.05). By adding rapamycin (1 ng/mL) and silymarin (25, 50, 100 μg/mL) over 24 hours, silymarin inhibited the pro-apoptotic effect of rapamycin on EPCs, and reversed the inhibition of proliferation, migration and angiogenesis of EPCs by rapamycin (P<0.05).
ParzonkoA, NaruszewicsM. (2010) Silymarin inhibits endothelial progenitor cells’ senescence and protects against the antiproliferative activity of rapamycin: preliminary study. Journal of Cardiovascular Pharmacology, 56, 610–618.
2.
WalterDH, RittigK, BahlmannFH, KirchmairR, SilverM, MurayamaT, NishimuraH, LosordoDW, AsaharaT, IsnerJM. (2002) Statin therapy accelerates reendotheliazation: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation, 105, 3017–3024.
3.
GrieseDP, EhsanA, MeloLG, KongD, ZhangL, MannMJ, PrattRE, MulliganRC, DzauVJ. (2003) Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation, 108, 2710–2715.
4.
HillJM, ZalosG, HalcoxJP, SchenkeWH, WaclawiwMA, QuyyumiAA, FinkelT. (2003) Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. The New England Journal of Medicine, 348, 593–600.
5.
GreiderCW, BlackburnEH. (1985) Identification of a specific telomere terminal transferase activity in tetrahymena extracts. Cell, 43, 405–413.
6.
GreiderCW, BlackburnEH. (1989) A telomeric sequence in the RNA of tetrahymena telomerase required for telomere repeat synthesis. Nature, 37, 331–337.
7.
FengJ, FunkWD, WangSS, WeinrichSL, AvilionAA, ChiuCP, AdamsRR, ChangE, AllsoppRC, YuJ. (1995) The RNA component of human telomerase. Science, 269, 1236–1241.
GreiderCW. (1998) Telomerase activity, cell proliferation, and cancer. Proceedings of the National Academy of Sciences of the United States of America, 95, 90–92.
10.
ImanishiT, KobayashiK, KukiS, TakahashiC, AkasakaT. (2006). Sirolimus accelerates senescence of endothelial progenitor cells through telomerase inactivation. Atherosclerosis, 189, 288–296.
MilićN, MiloševićN, SuvajdžićL, ŽarkovM, AbenavoliL. (2013) New therapeutic potentials of milk thistle (Silybum marianum). Natural Product Communications, 8, 1801–1810.
13.
ChenH, ZhangHT, WeiT, ShenQ. (1990) The protective effect of silybin cultured cardiomyocytes during hypoxia and glucose deprivation. Academic Journal of Second Military Medical University, 11, 147–149.
14.
WangC, WangMW, TashiroS, OnoderaS, IkejimaT. (2004) Human interleukin 1β induced apoptosis of human melanoma A375-S2 by caspase pathway. Chinese Journal of Pathophysiology, 20, 1138–1143.
15.
LiHM, WuJL, TashiroS, OnoderaS, UchiumiF, IkejimaT. (2005) Preventive effect of silymarin on UV irradiation-induced A375-S2 cell apoptosis. Chinese Journal of Pathophysiology, 21, 1873–1878.
16.
PatelN, JosephC, CorcoranGB, RaySD. (2010) Silymarin modulates doxorubicin induced oxidative stress, Bcl-xL and p53 expression while preventing apoptotic and necrotic cell death in the liver. Toxicology and Applied Pharmacology, 245, 143–152.
17.
BoyerM, TownsendLE, VogelLM, FalkJ, Reitz-VickD, TrevorKT, VillalbaM, BendickPJ, GloverJL. (2000) Isolation of endothelial cells and their progenitor cells from human peripheral blood. Journal of Vascular Surgery, 31, 181–189.
